Lewis Jennifer D, Payton Laura A, Whitford Jill G, Byrne Jennifer A, Smith David I, Yang Libang, Bright Robert K
Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 6591, Lubbock, TX 79430, USA.
Mol Cancer Res. 2007 Feb;5(2):133-44. doi: 10.1158/1541-7786.MCR-06-0245.
Expression studies have consistently identified tumor protein D52 (TPD52) overexpression in tumor cells. Murine TPD52 (mD52) shares 86% identity with the human orthologue. To study a possible role for TPD52 in transformation, 3T3 fibroblasts were transfected with the full-length cDNA for mD52. Expression of mD52 was confirmed by reverse transcription-PCR (RT-PCR), real-time PCR, and Western blot analysis compared with 3T3 and vector-transfected 3T3 (3T3.V), and the resultant cell line was designated 3T3.mD52. At 4 weeks, 3T3.mD52 gained a 2-fold increase in growth rate, lost contact inhibition, and exhibited a marked phenotype change. Further characterization revealed an acquired ability for anchorage-independent cell growth. To determine whether 3T3.mD52 had become tumorigenic, naïve, healthy, immunocompetent syngeneic mice were inoculated subcutaneously with varying cell doses. Tumors measuring >1 cm(2) were detected 60 days postinoculation with 3T3.mD52, and a 50% subcutaneous tumor incidence was obtained with as few as 5 x 10(5) 3T3.mD52 cells. Remarkably, when lungs from 3T3.mD52 tumor-bearing mice were analyzed, numerous tumor nodules were observed, ranging from nodules less than 10 to nodules too numerous to count (inoculation with 1 x 10(5) and 5 x 10(6) cells, respectively). Further support for the metastatic capacity of 3T3.mD52 was the demonstration that transforming growth factor (TGF)-betaR1 (receptor) expression decreased and TGF-beta1 secretion increased in 3T3.mD52 compared with 3T3 controls. cDNA microarray analysis showed a gene expression pattern that further supported mD52-induced transformation and metastasis. Together, these data suggest that mD52 expression in 3T3 cells initiated cellular transformation, tumorigenesis, and progression to metastasis.
表达研究一直发现肿瘤蛋白D52(TPD52)在肿瘤细胞中过表达。小鼠TPD52(mD52)与人同源物的同一性为86%。为了研究TPD52在细胞转化中的可能作用,用mD52的全长cDNA转染3T3成纤维细胞。通过逆转录PCR(RT-PCR)、实时PCR和蛋白质免疫印迹分析,与3T3和载体转染的3T3(3T3.V)相比,证实了mD52的表达,所得细胞系命名为3T3.mD52。4周时,3T3.mD52的生长速率增加了2倍,失去接触抑制,并表现出明显的表型变化。进一步的特征分析显示其获得了非锚定依赖的细胞生长能力。为了确定3T3.mD52是否具有致瘤性,将不同细胞剂量的3T3.mD52皮下接种到未经处理的、健康的、具有免疫活性的同基因小鼠体内。接种3T3.mD52后60天检测到肿瘤大小>1 cm²,接种低至5×10⁵个3T3.mD52细胞时皮下肿瘤发生率为50%。值得注意的是,分析3T3.mD52荷瘤小鼠的肺时,观察到大量肿瘤结节,结节大小从小于10个到多得数不清(分别接种1×10⁵和5×10⁶个细胞)。3T3.mD52具有转移能力的进一步证据是,与3T3对照相比,3T3.mD52中转化生长因子(TGF)-βR1(受体)表达降低,TGF-β1分泌增加。cDNA微阵列分析显示的基因表达模式进一步支持了mD52诱导的细胞转化和转移。这些数据共同表明,3T3细胞中mD52的表达引发了细胞转化、肿瘤发生及向转移的进展。